Eldad Melamed - Publications

Affiliations: 
Tel Aviv University, Tel Aviv-Yafo, Tel Aviv District, Israel 

202 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Petrou P, Gothelf Y, Argov Z, Gotkine M, Levy YS, Kassis I, Vaknin-Dembinsky A, Ben-Hur T, Offen D, Abramsky O, Melamed E, Karussis D. Safety and Clinical Effects of Mesenchymal Stem Cells Secreting Neurotrophic Factor Transplantation in Patients With Amyotrophic Lateral Sclerosis: Results of Phase 1/2 and 2a Clinical Trials. Jama Neurology. 1-8. PMID 26751635 DOI: 10.1001/jamaneurol.2015.4321  0.31
2015 Benninger F, Khlebtovsky A, Roditi Y, Keret O, Steiner I, Melamed E, Djaldetti R. Beneficial effect of levodopa therapy on stooped posture in Parkinson's disease. Gait & Posture. 42: 263-8. PMID 26055804 DOI: 10.1016/j.gaitpost.2015.05.015  0.305
2015 Lev N, Barhum Y, Ben-Zur T, Aharony I, Trifonov L, Regev N, Melamed E, Gruzman A, Offen D. A DJ-1 Based Peptide Attenuates Dopaminergic Degeneration in Mice Models of Parkinson's Disease via Enhancing Nrf2. Plos One. 10: e0127549. PMID 26024237 DOI: 10.1371/journal.pone.0127549  0.381
2014 Lamm O, Ganz J, Melamed E, Offen D. Harnessing neurogenesis for the possible treatment of Parkinson's disease. The Journal of Comparative Neurology. 522: 2817-30. PMID 24723264 DOI: 10.1002/cne.23607  0.408
2014 de Munter JP, Melamed E, Wolters ECh. Stem cell grafting in parkinsonism--why, how and when. Parkinsonism & Related Disorders. 20: S150-3. PMID 24262169 DOI: 10.1016/S1353-8020(13)70036-1  0.317
2013 Greenbaum L, Lorberboym M, Melamed E, Rigbi A, Barhum Y, Kohn Y, Khlebtovsky A, Lerer B, Djaldetti R. Perspective: Identification of genetic variants associated with dopaminergic compensatory mechanisms in early Parkinson's disease. Frontiers in Neuroscience. 7: 52. PMID 23596382 DOI: 10.3389/fnins.2013.00052  0.393
2013 Lev N, Barhum Y, Ben-Zur T, Melamed E, Steiner I, Offen D. Knocking out DJ-1 attenuates astrocytes neuroprotection against 6-hydroxydopamine toxicity. Journal of Molecular Neuroscience : Mn. 50: 542-50. PMID 23536331 DOI: 10.1007/s12031-013-9984-9  0.379
2013 Lang AE, Melamed E, Poewe W, Rascol O. Trial designs used to study neuroprotective therapy in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 28: 86-95. PMID 22927060 DOI: 10.1002/mds.24997  0.331
2013 Lev N, Barhum Y, Pilosof NS, Ickowicz D, Cohen HY, Melamed E, Offen D. DJ-1 protects against dopamine toxicity: implications for Parkinson's disease and aging. The Journals of Gerontology. Series a, Biological Sciences and Medical Sciences. 68: 215-25. PMID 22887838 DOI: 10.1093/gerona/gls147  0.429
2012 Dadon-Nachum M, Ben-Zur T, Srugo I, Shamir HM, Melamed E, Yaffe D, Offen D. Therapeutic effect of myogenic cells modified to express neurotrophic factors in a rat model of sciatic nerve injury. Journal of Stem Cells & Regenerative Medicine. 8: 21-7. PMID 24693189 DOI: 10.46582/Jsrm.0801004  0.322
2012 Shruster A, Ben-Zur T, Melamed E, Offen D. Wnt signaling enhances neurogenesis and improves neurological function after focal ischemic injury. Plos One. 7: e40843. PMID 22815838 DOI: 10.1371/journal.pone.0040843  0.301
2012 Khlebtovsky A, Rigbi A, Melamed E, Ziv I, Steiner I, Gad A, Djaldetti R. Patient and caregiver perceptions of the social impact of advanced Parkinson's disease and dyskinesias. Journal of Neural Transmission (Vienna, Austria : 1996). 119: 1367-71. PMID 22437202 DOI: 10.1007/s00702-012-0796-9  0.305
2012 Sadan O, Shemesh N, Barzilay R, Dadon-Nahum M, Blumenfeld-Katzir T, Assaf Y, Yeshurun M, Djaldetti R, Cohen Y, Melamed E, Offen D. Mesenchymal stem cells induced to secrete neurotrophic factors attenuate quinolinic acid toxicity: a potential therapy for Huntington's disease. Experimental Neurology. 234: 417-27. PMID 22285250 DOI: 10.1016/j.expneurol.2011.12.045  0.355
2012 Melamed E, Poewe W. Taking sides: is handedness involved in motor asymmetry of Parkinson's disease? Movement Disorders : Official Journal of the Movement Disorder Society. 27: 171-3. PMID 22223083 DOI: 10.1002/mds.24048  0.313
2012 Lev N, Barhum Y, Ben-Tzur T, Melamed E, Offen D. DJ-1 Based Peptide as a Novel Neuroprotective Strategy for Parkinson's Disease (SC02.003) Neurology. 78. DOI: 10.1212/Wnl.78.1_Meetingabstracts.Sc02.003  0.378
2011 Barzilay R, Ben-Zur T, Sadan O, Bren Z, Taler M, Lev N, Tarasenko I, Uzan R, Gil-Ad I, Melamed E, Weizman A, Offen D. Intracerebral adult stem cells transplantation increases brain-derived neurotrophic factor levels and protects against phencyclidine-induced social deficit in mice. Translational Psychiatry. 1: e61. PMID 22832353 DOI: 10.1038/tp.2011.64  0.323
2011 Ganz J, Lev N, Melamed E, Offen D. Cell replacement therapy for Parkinson's disease: how close are we to the clinic? Expert Review of Neurotherapeutics. 11: 1325-39. PMID 21864078 DOI: 10.1586/ern.11.74  0.392
2011 Vilariño-Güell C, Wider C, Ross OA, Dachsel JC, Kachergus JM, Lincoln SJ, Soto-Ortolaza AI, Cobb SA, Wilhoite GJ, Bacon JA, Behrouz B, Melrose HL, Hentati E, Puschmann A, Evans DM, ... ... Melamed E, et al. VPS35 mutations in Parkinson disease. American Journal of Human Genetics. 89: 162-7. PMID 21763482 DOI: 10.1016/j.ajhg.2011.06.001  0.308
2011 Rascol O, Fitzer-Attas CJ, Hauser R, Jankovic J, Lang A, Langston JW, Melamed E, Poewe W, Stocchi F, Tolosa E, Eyal E, Weiss YM, Olanow CW. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. The Lancet. Neurology. 10: 415-23. PMID 21482191 DOI: 10.1016/S1474-4422(11)70073-4  0.312
2011 Dadon-Nachum M, Sadan O, Srugo I, Melamed E, Offen D. Differentiated mesenchymal stem cells for sciatic nerve injury. Stem Cell Reviews. 7: 664-71. PMID 21327572 DOI: 10.1007/s12015-010-9227-1  0.328
2011 Inzelberg R, Rabey JM, Melamed E, Djaldetti R, Reches A, Badarny S, Hassin-Baer S, Cohen O, Trau H, Aharon-Peretz J, Milo R, Schwartz M, Huberman M, Gilead L, Barchana M, et al. High prevalence of malignant melanoma in Israeli patients with Parkinson's disease. Journal of Neural Transmission (Vienna, Austria : 1996). 118: 1199-207. PMID 21298300 DOI: 10.1007/S00702-011-0580-2  0.329
2011 Shruster A, Eldar-Finkelman H, Melamed E, Offen D. Wnt signaling pathway overcomes the disruption of neuronal differentiation of neural progenitor cells induced by oligomeric amyloid β-peptide. Journal of Neurochemistry. 116: 522-9. PMID 21138436 DOI: 10.1111/j.1471-4159.2010.07131.x  0.308
2011 Dadon-Nachum M, Melamed E, Offen D. The "dying-back" phenomenon of motor neurons in ALS. Journal of Molecular Neuroscience : Mn. 43: 470-7. PMID 21057983 DOI: 10.1007/s12031-010-9467-1  0.316
2011 Djaldetti R, Lorberboym M, Karmon Y, Treves TA, Ziv I, Melamed E. Residual striatal dopaminergic nerve terminals in very long-standing Parkinson's disease: a single photon emission computed tomography imaging study. Movement Disorders : Official Journal of the Movement Disorder Society. 26: 327-30. PMID 20939078 DOI: 10.1002/mds.23380  0.394
2011 Kan I, Barhum Y, Melamed E, Offen D. Mesenchymal stem cells stimulate endogenous neurogenesis in the subventricular zone of adult mice. Stem Cell Reviews. 7: 404-12. PMID 20830611 DOI: 10.1007/s12015-010-9190-x  0.302
2010 Hellmann MA, Melamed E, Steinmetz AP, Djaldetti R. Unilateral lower limb rest tremor is not necessarily a presenting symptom of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 25: 924-7. PMID 20198647 DOI: 10.1002/mds.23030  0.359
2010 Shemesh N, Sadan O, Melamed E, Offen D, Cohen Y. Longitudinal MRI and MRSI characterization of the quinolinic acid rat model for excitotoxicity: peculiar apparent diffusion coefficients and recovery of N-acetyl aspartate levels. Nmr in Biomedicine. 23: 196-206. PMID 19950122 DOI: 10.1002/nbm.1443  0.339
2010 Sadan O, Shemesh N, Melamed E, Offen D, Cohen Y. I11 Longitudinal MRI and MRSI characterisation of the quinolinic acid rat model for excitotoxicity: unique recovery of N-acetyl aspartate levels Journal of Neurology, Neurosurgery & Psychiatry. 81: A39.3-A39. DOI: 10.1136/jnnp.2010.222679.11  0.339
2010 Sadan O, Shemesh N, Cohen Y, Melamed E, Offen D. B15 Rat bone marrow derived mesenchymal stem cells post differentiation to neurotrophic factor secreting cells migrate towards quinolinic acid lesion Journal of Neurology, Neurosurgery & Psychiatry. 81: A15.3-A16. DOI: 10.1136/jnnp.2010.222596.15  0.337
2010 Sadan O, Barzilay R, Melamed E, Offen D. B14 Neurotrophic factors secreting mesenchymal stem cells attenuate quinolinic acid induced striatal lesion model suggesting autologous therapy for HD Journal of Neurology, Neurosurgery & Psychiatry. 81: A15.2-A15. DOI: 10.1136/jnnp.2010.222596.14  0.352
2009 Djaldetti R, Treves TA, Ziv I, Melamed E, Lampl Y, Lorberboym M. Use of a single [123I]-FP-CIT SPECT to predict the severity of clinical symptoms of Parkinson disease. Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 30: 301-5. PMID 19499179 DOI: 10.1007/s10072-009-0100-4  0.362
2009 Barzilay R, Ben-Zur T, Bulvik S, Melamed E, Offen D. Lentiviral delivery of LMX1a enhances dopaminergic phenotype in differentiated human bone marrow mesenchymal stem cells. Stem Cells and Development. 18: 591-601. PMID 19298173 DOI: 10.1089/scd.2008.0138  0.302
2009 Sadan O, Bahat-Stromza M, Barhum Y, Levy YS, Pisnevsky A, Peretz H, Ilan AB, Bulvik S, Shemesh N, Krepel D, Cohen Y, Melamed E, Offen D. Protective effects of neurotrophic factor-secreting cells in a 6-OHDA rat model of Parkinson disease. Stem Cells and Development. 18: 1179-90. PMID 19243240 DOI: 10.1089/scd.2008.0411  0.404
2009 Djaldetti R, Lev N, Melamed E. Lesions outside the CNS in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 24: 793-800. PMID 19224610 DOI: 10.1002/mds.22172  0.371
2009 Bahat-Stroomza M, Barhum Y, Levy YS, Karpov O, Bulvik S, Melamed E, Offen D. Induction of adult human bone marrow mesenchymal stromal cells into functional astrocyte-like cells: potential for restorative treatment in Parkinson's disease. Journal of Molecular Neuroscience : Mn. 39: 199-210. PMID 19127447 DOI: 10.1007/s12031-008-9166-3  0.408
2009 Lev N, Ickowicz D, Barhum Y, Lev S, Melamed E, Offen D. DJ-1 protects against dopamine toxicity. Journal of Neural Transmission (Vienna, Austria : 1996). 116: 151-60. PMID 18974921 DOI: 10.1007/s00702-008-0134-4  0.417
2008 Olanow CW, Hauser RA, Jankovic J, Langston W, Lang A, Poewe W, Tolosa E, Stocchi F, Melamed E, Eyal E, Rascol O. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. Movement Disorders : Official Journal of the Movement Disorder Society. 23: 2194-201. PMID 18932271 DOI: 10.1002/mds.22218  0.31
2008 Djaldetti R, Hassin-Baer S, Farrer MJ, Vilariño-Güell C, Ross OA, Kolianov V, Yust-Katz S, Treves TA, Barhum Y, Hulihan M, Melamed E. Clinical characteristics of Parkinson's disease among Jewish Ethnic groups in Israel. Journal of Neural Transmission (Vienna, Austria : 1996). 115: 1279-84. PMID 18665323 DOI: 10.1007/s00702-008-0074-z  0.327
2008 Sadan O, Shemesh N, Barzilay R, Bahat-Stromza M, Melamed E, Cohen Y, Offen D. Migration of neurotrophic factors-secreting mesenchymal stem cells toward a quinolinic acid lesion as viewed by magnetic resonance imaging. Stem Cells (Dayton, Ohio). 26: 2542-51. PMID 18635865 DOI: 10.1634/stemcells.2008-0240  0.32
2008 Levy YS, Bahat-Stroomza M, Barzilay R, Burshtein A, Bulvik S, Barhum Y, Panet H, Melamed E, Offen D. Regenerative effect of neural-induced human mesenchymal stromal cells in rat models of Parkinson's disease. Cytotherapy. 10: 340-52. PMID 18574767 DOI: 10.1080/14653240802021330  0.375
2008 Barzilay R, Kan I, Ben-Zur T, Bulvik S, Melamed E, Offen D. Induction of human mesenchymal stem cells into dopamine-producing cells with different differentiation protocols. Stem Cells and Development. 17: 547-54. PMID 18513164 DOI: 10.1089/scd.2007.0172  0.403
2008 Lev N, Ickowicz D, Melamed E, Offen D. Oxidative insults induce DJ-1 upregulation and redistribution: implications for neuroprotection. Neurotoxicology. 29: 397-405. PMID 18377993 DOI: 10.1016/j.neuro.2008.01.007  0.348
2008 Yust-Katz S, Tesler D, Treves TA, Melamed E, Djaldetti R. Handedness as a predictor of side of onset of Parkinson's disease. Parkinsonism & Related Disorders. 14: 633-5. PMID 18346926 DOI: 10.1016/j.parkreldis.2008.01.017  0.326
2008 Yust-Katz S, Sthneer S, Melamed E, Djaldetti R. Long-term Parkinson's disease--time for optimism. Biomedicine & Pharmacotherapy = Biomã©Decine & Pharmacothã©Rapie. 62: 233-5. PMID 18294809 DOI: 10.1016/j.biopha.2007.12.014  0.344
2008 Djaldetti R, Nageris BI, Lorberboym M, Treves TA, Melamed E, Yaniv E. [(123)I]-FP-CIT SPECT and olfaction test in patients with combined postural and rest tremor. Journal of Neural Transmission (Vienna, Austria : 1996). 115: 469-72. PMID 18250955 DOI: 10.1007/s00702-007-0851-0  0.315
2008 Hellmann MA, Sabach T, Melamed E, Djaldetti R. Effect of subcutaneous apomorphine on tremor in idiopathic Parkinson's disease. Biomedicine & Pharmacotherapy = Biomã©Decine & Pharmacothã©Rapie. 62: 250-2. PMID 17967525 DOI: 10.1016/j.biopha.2007.09.002  0.403
2007 Lev N, Melamed E, Offen D. Toxic causes of parkinsonism. Handbook of Clinical Neurology. 84: 385-98. PMID 18808959 DOI: 10.1016/S0072-9752(07)84050-4  0.402
2007 Melamed E, Ziv I, Djaldetti R. Management of motor complications in advanced Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 22: S379-84. PMID 18175400 DOI: 10.1002/mds.21680  0.381
2007 Djaldetti R, Treves TA, Ziv I, Melamed E, Lorberboym M. 123I-FP-CIT SPECT imaging of dopamine transporters in patients with recurrent sudden falls: are such falls a distinct entity? Journal of Nuclear Medicine Technology. 35: 232-6. PMID 18006592 DOI: 10.2967/jnmt.107.040238  0.338
2007 Offen D, Barhum Y, Levy YS, Burshtein A, Panet H, Cherlow T, Melamed E. Intrastriatal transplantation of mouse bone marrow-derived stem cells improves motor behavior in a mouse model of Parkinson's disease. Journal of Neural Transmission. Supplementum. 133-43. PMID 17982886 DOI: 10.1007/978-3-211-73574-9-16  0.384
2007 Litvan I, Chesselet MF, Gasser T, Di Monte DA, Parker D, Hagg T, Hardy J, Jenner P, Myers RH, Price D, Hallett M, Langston WJ, Lang AE, Halliday G, Rocca W, ... ... Melamed E, et al. The etiopathogenesis of Parkinson disease and suggestions for future research. Part II. Journal of Neuropathology and Experimental Neurology. 66: 329-36. PMID 17483689 DOI: 10.1097/Nen.0B013E318053716A  0.318
2007 Kan I, Ben-Zur T, Barhum Y, Levy YS, Burstein A, Charlow T, Bulvik S, Melamed E, Offen D. Dopaminergic differentiation of human mesenchymal stem cells--utilization of bioassay for tyrosine hydroxylase expression. Neuroscience Letters. 419: 28-33. PMID 17475405 DOI: 10.1016/j.neulet.2007.03.070  0.415
2007 Kan I, Melamed E, Offen D, Green P. Docosahexaenoic acid and arachidonic acid are fundamental supplements for the induction of neuronal differentiation. Journal of Lipid Research. 48: 513-7. PMID 17185746 DOI: 10.1194/jlr.C600022-JLR200  0.327
2007 Lev N, Djaldetti R, Melamed E. Initiation of symptomatic therapy in Parkinson's disease: Dopamine agonists versus levodopa Journal of Neurology. 254: 19-26. DOI: 10.1007/s00415-007-5004-8  0.387
2006 Melamed E, Djaldetti R. Camptocormia in Parkinson's disease. Journal of Neurology. 253: VII14-16. PMID 17131221 DOI: 10.1007/s00415-006-7004-5  0.371
2006 Lev N, Roncevic D, Roncevich D, Ickowicz D, Melamed E, Offen D. Role of DJ-1 in Parkinson's disease. Journal of Molecular Neuroscience : Mn. 29: 215-25. PMID 17085780 DOI: 10.1385/JMN:29:3:215  0.342
2006 Gilgun-Sherki Y, Melamed E, Offen D. Anti-inflammatory drugs in the treatment of neurodegenerative diseases: current state. Current Pharmaceutical Design. 12: 3509-19. PMID 17017944 DOI: 10.2174/138161206778343091  0.312
2006 Hellmann MA, Djaldetti R, Israel Z, Melamed E. Effect of deep brain subthalamic stimulation on camptocormia and postural abnormalities in idiopathic Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 21: 2008-10. PMID 16972244 DOI: 10.1002/mds.21090  0.36
2006 Djaldetti R, Ziv I, Melamed E. The mystery of motor asymmetry in Parkinson's disease. The Lancet. Neurology. 5: 796-802. PMID 16914408 DOI: 10.1016/S1474-4422(06)70549-X  0.329
2006 Dabby R, Djaldetti R, Shahmurov M, Treves TA, Gabai B, Melamed E, Sadeh M, Avinoach I. Skin biopsy for assessment of autonomic denervation in Parkinson's disease. Journal of Neural Transmission (Vienna, Austria : 1996). 113: 1169-76. PMID 16835698 DOI: 10.1007/s00702-005-0431-0  0.336
2006 Oved D, Ziv I, Treves TA, Paleacu D, Melamed E, Djaldetti R. Effect of dopamine agonists on fatigue and somnolence in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 21: 1257-61. PMID 16685690 DOI: 10.1002/mds.20929  0.392
2006 Lev N, Melamed E, Offen D. Proteasomal inhibition hypersensitizes differentiated neuroblastoma cells to oxidative damage. Neuroscience Letters. 399: 27-32. PMID 16584840 DOI: 10.1016/j.neulet.2005.09.086  0.32
2006 Hellmann MA, Panet H, Barhum Y, Melamed E, Offen D. Increased survival and migration of engrafted mesenchymal bone marrow stem cells in 6-hydroxydopamine-lesioned rodents. Neuroscience Letters. 395: 124-8. PMID 16359791 DOI: 10.1016/j.neulet.2005.10.097  0.364
2006 Lorberboym M, Treves TA, Melamed E, Lampl Y, Hellmann M, Djaldetti R. [123I]-FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 21: 510-4. PMID 16250023 DOI: 10.1002/mds.20748  0.396
2005 Levy YS, Gilgun-Sherki Y, Melamed E, Offen D. Therapeutic potential of neurotrophic factors in neurodegenerative diseases. Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy. 19: 97-127. PMID 15807629 DOI: 10.2165/00063030-200519020-00003  0.36
2005 Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F, Tolosa E. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet. 365: 947-54. PMID 15766996 DOI: 10.1016/S0140-6736(05)71083-7  0.332
2005 Bahat-Stroomza M, Gilgun-Sherki Y, Offen D, Panet H, Saada A, Krool-Galron N, Barzilai A, Atlas D, Melamed E. A novel thiol antioxidant that crosses the blood brain barrier protects dopaminergic neurons in experimental models of Parkinson's disease. The European Journal of Neuroscience. 21: 637-46. PMID 15733082 DOI: 10.1111/j.1460-9568.2005.03889.x  0.439
2005 Olanow CW, Agid Y, Mizuno Y, Albanese A, Bonuccelli U, Damier P, Yebenes JD, Gershanik O, Guttman M, Grandas F, Hallett M, Hornykiewicz O, Jenner P, Katzenschlager R, Langston WJ, ... ... Melamed E, et al. Erratum: Levodopa in the treatment of Parkinson's disease: Current controversies (Movement Disorders) (2004)) Movement Disorders. 20. DOI: 10.1002/Mds.20519  0.302
2004 Elkon H, Melamed E, Offen D. Oxidative stress, induced by 6-hydroxydopamine, reduces proteasome activities in PC12 cells: implications for the pathogenesis of Parkinson's disease. Journal of Molecular Neuroscience : Mn. 24: 387-400. PMID 15655261 DOI: 10.1385/JMN:24:3:387  0.378
2004 Levy YS, Stroomza M, Melamed E, Offen D. Embryonic and adult stem cells as a source for cell therapy in Parkinson's disease. Journal of Molecular Neuroscience : Mn. 24: 353-86. PMID 15655260 DOI: 10.1385/JMN:24:3:353  0.421
2004 Djaldetti R, Hellmann M, Melamed E. Bent knees and tiptoeing: late manifestations of end-stage Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 19: 1325-8. PMID 15389997 DOI: 10.1002/mds.20187  0.34
2004 Olanow CW, Agid Y, Mizuno Y, Albanese A, Bonuccelli U, Bonucelli U, Damier P, De Yebenes J, Gershanik O, Guttman M, Grandas F, Hallett M, Hornykiewicz O, Jenner P, Katzenschlager R, ... ... Melamed E, et al. Levodopa in the treatment of Parkinson's disease: current controversies. Movement Disorders : Official Journal of the Movement Disorder Society. 19: 997-1005. PMID 15372588 DOI: 10.1002/Mds.20243  0.397
2004 Gilgun-Sherki Y, Djaldetti R, Melamed E, Offen D. Polymorphism in candidate genes: implications for the risk and treatment of idiopathic Parkinson's disease. The Pharmacogenomics Journal. 4: 291-306. PMID 15224083 DOI: 10.1038/sj.tpj.6500260  0.364
2004 Bulvik S, Ben-Zur T, Levy YS, Burshtein A, Melamed E, Offen D. Transcription Factors Analysis in Neuronal-Like Cells Derived from Adult Human Bone Marrow. Blood. 104: 4172-4172. DOI: 10.1182/Blood.V104.11.4172.4172  0.354
2003 Djaldetti R, Giladi N, Hassin-Baer S, Shabtai H, Melamed E. Pharmacokinetics of etilevodopa compared to levodopa in patients with Parkinson's disease: an open-label, randomized, crossover study. Clinical Neuropharmacology. 26: 322-6. PMID 14646613 DOI: 10.1097/00002826-200311000-00012  0.355
2003 Levy YS, Merims D, Panet H, Barhum Y, Melamed E, Offen D. Induction of neuron-specific enolase promoter and neuronal markers in differentiated mouse bone marrow stromal cells. Journal of Molecular Neuroscience : Mn. 21: 121-32. PMID 14593212 DOI: 10.1385/JMN:21:2:121  0.347
2003 Gilgun-Sherki Y, Melamed E, Mechoulam R, Offen D. The CB1 cannabinoid receptor agonist, HU-210, reduces levodopa-induced rotations in 6-hydroxydopamine-lesioned rats. Pharmacology & Toxicology. 93: 66-70. PMID 12899667 DOI: 10.1034/J.1600-0773.2003.930202.X  0.414
2003 Merims D, Djaldetti R, Melamed E. Waiting for ON: a major problem in patients with Parkinson disease and ON/OFF motor fluctuations. Clinical Neuropharmacology. 26: 196-8. PMID 12897640 DOI: 10.1097/00002826-200307000-00009  0.306
2003 Barzilai A, Melamed E. Molecular mechanisms of selective dopaminergic neuronal death in Parkinson's disease. Trends in Molecular Medicine. 9: 126-32. PMID 12657434 DOI: 10.1016/S1471-4914(03)00020-0  0.38
2003 Lev N, Melamed E, Offen D. Apoptosis and Parkinson's disease. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 27: 245-50. PMID 12657363 DOI: 10.1016/S0278-5846(03)00019-8  0.382
2003 Djaldetti R, Treves TA, Merims D, Sroka H, Melamed E. Effect of late initiation of levodopa treatment in patients with long-standing Parkinson's disease. Clinical Neuropharmacology. 26: 24-7. PMID 12567161 DOI: 10.1097/00002826-200301000-00006  0.362
2002 Levy YS, Streifler JY, Panet H, Melamed E, Offen D. Hemin-induced apoptosis in PC12 and neuroblastoma cells: implications for local neuronal death associated with intracerebral hemorrhage. Neurotoxicity Research. 4: 609-616. PMID 12709299 DOI: 10.1080/1029842021000045624  0.303
2002 Shirvan A, Kimron M, Holdengreber V, Ziv I, Ben-Shaul Y, Melamed S, Melamed E, Barzilai A, Solomon AS. Anti-semaphorin 3A antibodies rescue retinal ganglion cells from cell death following optic nerve axotomy. The Journal of Biological Chemistry. 277: 49799-807. PMID 12376549 DOI: 10.1074/jbc.M204793200  0.301
2002 Djaldetti R, Melamed E. New drugs in the future treatment of Parkinson's disease. Journal of Neurology. 249: II30-5. PMID 12375061 DOI: 10.1007/s00415-002-1206-2  0.359
2002 Djaldetti R, Ziv I, Melamed E. The effect of deprenyl washout in patients with long-standing Parkinson's disease. Journal of Neural Transmission (Vienna, Austria : 1996). 109: 797-803. PMID 12111469 DOI: 10.1007/s007020200066  0.326
2001 Ziv I, Shirvan A, Offen D, Barzilai A, Melamed E. Molecular biology of dopamine-induced apoptosis : possible implications for Parkinson's disease. Methods in Molecular Medicine. 62: 73-87. PMID 21318769 DOI: 10.1385/1-59259-142-6:73  0.37
2001 Elkon H, Melamed E, Offen D. 6-Hydroxydopamine increases ubiquitin-conjugates and protein degradation: implications for the pathogenesis of Parkinson's disease. Cellular and Molecular Neurobiology. 21: 771-81. PMID 12043847 DOI: 10.1023/A:1015160323009  0.359
2001 Offen D, Shtaif B, Hadad D, Weizman A, Melamed E, Gil-Ad I. Protective effect of insulin-like-growth-factor-1 against dopamine-induced neurotoxicity in human and rodent neuronal cultures: possible implications for Parkinson's disease. Neuroscience Letters. 316: 129-32. PMID 11744219 DOI: 10.1016/S0304-3940(01)02344-8  0.417
2001 Barzilai A, Melamed E, Shirvan A. Is there a rationale for neuroprotection against dopamine toxicity in Parkinson's disease? Cellular and Molecular Neurobiology. 21: 215-35. PMID 11569535 DOI: 10.1023/A:1010991020245  0.427
2001 Djaldetti R, Melamed E. New therapies for Parkinson's disease. Journal of Neurology. 248: 357-62. PMID 11437155 DOI: 10.1007/S004150170174  0.38
2001 Djaldetti R, Rosmarin V, Ziv I, Melamed E. The pharmacokinetic profile of the "first ever" oral dose of levodopa in de novo patients with Parkinson's disease. Clinical Neuropharmacology. 24: 95-8. PMID 11307044 DOI: 10.1097/00002826-200103000-00005  0.371
2001 Panet H, Barzilai A, Daily D, Melamed E, Offen D. Activation of nuclear transcription factor kappa B (NF-kappaB) is essential for dopamine-induced apoptosis in PC12 cells. Journal of Neurochemistry. 77: 391-8. PMID 11299301 DOI: 10.1046/j.1471-4159.2001.00213.x  0.342
2001 Albanese A, Bonuccelli U, Brefel C, Chaudhuri KR, Colosimo C, Eichhorn T, Melamed E, Pollak P, Van Laar T, Zappia M. Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 16: 197-201. PMID 11295770 DOI: 10.1002/Mds.1069  0.308
2001 Offen D, Panet H, Galili-Mosberg R, Melamed E. Catechol-O-methyltransferase decreases levodopa toxicity in vitro. Clinical Neuropharmacology. 24: 27-30. PMID 11290879 DOI: 10.1097/00002826-200101000-00006  0.307
2001 Daily D, Vlamis-Gardikas A, Offen D, Mittelman L, Melamed E, Holmgren A, Barzilai A. Glutaredoxin protects cerebellar granule neurons from dopamine-induced apoptosis by dual activation of the ras-phosphoinositide 3-kinase and jun n-terminal kinase pathways. The Journal of Biological Chemistry. 276: 21618-26. PMID 11290748 DOI: 10.1074/jbc.M101400200  0.302
2001 Daily D, Vlamis-Gardikas A, Offen D, Mittelman L, Melamed E, Holmgren A, Barzilai A. Glutaredoxin protects cerebellar granule neurons from dopamine-induced apoptosis by activating NF-kappa B via Ref-1. The Journal of Biological Chemistry. 276: 1335-44. PMID 11035035 DOI: 10.1074/jbc.M008121200  0.311
2000 Rabey JM, Sagi I, Huberman M, Melamed E, Korczyn A, Giladi N, Inzelberg R, Djaldetti R, Klein C, Berecz G. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa. Clinical Neuropharmacology. 23: 324-30. PMID 11575866 DOI: 10.1097/00002826-200011000-00005  0.367
2000 Galili R, Mosberg, Gil-Ad I, Weizman A, Melamed E, Offen D. Haloperidol-induced neurotoxicity--possible implications for tardive dyskinesia. Journal of Neural Transmission (Vienna, Austria : 1996). 107: 479-90. PMID 11215758 DOI: 10.1007/S007020070089  0.367
2000 Barzilai A, Zilkha-Falb R, Daily D, Stern N, Offen D, Ziv I, Melamed E, Shirvan A. The molecular mechanism of dopamine-induced apoptosis: identification and characterization of genes that mediate dopamine toxicity. Journal of Neural Transmission. Supplementum. 59-76. PMID 11205158 DOI: 10.1007/978-3-7091-6301-6_4  0.435
2000 Offen D, Elkon H, Melamed E. Apoptosis as a general cell death pathway in neurodegenerative diseases. Journal of Neural Transmission. Supplementum. 153-66. PMID 11128605 DOI: 10.1007/978-3-7091-6284-2_13  0.339
2000 Shirvan A, Shina R, Ziv I, Melamed E, Barzilai A. Induction of neuronal apoptosis by Semaphorin3A-derived peptide. Brain Research. Molecular Brain Research. 83: 81-93. PMID 11072098 DOI: 10.1016/S0169-328X(00)00198-4  0.307
2000 Merims D, Galili-Mosberg R, Melamed E. Is there addiction to levodopa in patients with Parkinson's disease? Movement Disorders : Official Journal of the Movement Disorder Society. 15: 1014-6. PMID 11009217 DOI: 10.1002/1531-8257(200009)15:5<1014::Aid-Mds1041>3.0.Co;2-O  0.357
2000 Melamed E, Offen D, Shirvan A, Ziv I. Levodopa--an exotoxin or a therapeutic drug? Journal of Neurology. 247: II135-9. PMID 10991660 DOI: 10.1007/Pl00022914  0.395
2000 Zilkha-Falb R, Barzilai A, Djaldeti R, Ziv I, Melamed E, Shirvan A. Involvement of T-complex protein-1delta in dopamine triggered apoptosis in chick embryo sympathetic neurons. The Journal of Biological Chemistry. 275: 36380-7. PMID 10954701 DOI: 10.1074/jbc.M001692200  0.375
2000 Offen D, Sherki Y, Melamed E, Fridkin M, Brenneman DE, Gozes I. Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease. Brain Research. 854: 257-62. PMID 10784133 DOI: 10.1016/S0006-8993(99)02375-6  0.577
1999 Agid Y, Ahlskog E, Albanese A, Calne D, Chase T, De Yebenes J, Factor S, Fahn S, Gershanik O, Goetz C, Koller W, Kurth M, Lang A, Lees A, Lewitt P, ... ... Melamed E, et al. Levodopa in the treatment of Parkinson's disease: a consensus meeting. Movement Disorders : Official Journal of the Movement Disorder Society. 14: 911-3. PMID 10584663 DOI: 10.1002/1531-8257(199911)14:6<911::Aid-Mds1001>3.0.Co;2-H  0.384
1999 Melamed E, Zoldan J, Galili-Mosberg R, Ziv I, Djaldetti R. Current management of motor fluctuations in patients with advanced Parkinson's disease treated chronically with levodopa. Journal of Neural Transmission. Supplementum. 56: 173-83. PMID 10370911 DOI: 10.1007/978-3-7091-6360-3_11  0.362
1999 Djaldetti R, Mosberg-Galili R, Sroka H, Merims D, Melamed E. Camptocormia (bent spine) in patients with Parkinson's disease--characterization and possible pathogenesis of an unusual phenomenon. Movement Disorders : Official Journal of the Movement Disorder Society. 14: 443-7. PMID 10348467 DOI: 10.1002/1531-8257(199905)14:3<443::Aid-Mds1009>3.0.Co;2-G  0.328
1999 Merims D, Ziv I, Djaldetti R, Melamed E. Riluzole for levodopa-induced dyskinesias in advanced Parkinson's disease. Lancet. 353: 1764-5. PMID 10347995 DOI: 10.1016/S0140-6736(99)00120-8  0.366
1999 Daily D, Barzilai A, Offen D, Kamsler A, Melamed E, Ziv I. The involvement of p53 in dopamine-induced apoptosis of cerebellar granule neurons and leukemic cells overexpressing p53. Cellular and Molecular Neurobiology. 19: 261-76. PMID 10081609 DOI: 10.1023/A:1006933312401  0.386
1999 Ziv I, Avraham M, Dabby R, Zoldan J, Djaldetti R, Melamed E. Early-occurrence of manual motor blocks in Parkinson's disease: a quantitative assessment. Acta Neurologica Scandinavica. 99: 106-11. PMID 10071169 DOI: 10.1111/J.1600-0404.1999.Tb00666.X  0.333
1999 Offen D, Gorodin S, Melamed E, Hanania J, Malik Z. Dopamine-melanin is actively phagocytized by PC12 cells and cerebellar granular cells: possible implications for the etiology of Parkinson's disease. Neuroscience Letters. 260: 101-4. PMID 10025709 DOI: 10.1016/S0304-3940(98)00950-1  0.407
1999 Giladi N, Melamed E. Levodopa therapy can ameliorate tetrabenazine-induced parkinsonism. Movement Disorders : Official Journal of the Movement Disorder Society. 14: 158-9. PMID 9918362 DOI: 10.1002/1531-8257(199901)14:1<158::Aid-Mds1028>3.0.Co;2-Q  0.314
1998 Ziv I, Avraham M, Michaelov Y, Djaldetti R, Dressler R, Zoldan J, Melamed E. Enhanced fatigue during motor performance in patients with Parkinson's disease. Neurology. 51: 1583-6. PMID 9855505 DOI: 10.1212/Wnl.51.6.1583  0.352
1998 Ziv I, Melamed E. Role of apoptosis in the pathogenesis of Parkinson's disease: A novel therapeutic opportunity? Movement Disorders : Official Journal of the Movement Disorder Society. 13: 865-70. PMID 9827608 DOI: 10.1002/mds.870130602  0.328
1998 Melamed E, Offen D, Shirvan A, Djaldetti R, Barzilai A, Ziv I. Levodopa toxicity and apoptosis. Annals of Neurology. 44: S149-54. PMID 9749587 DOI: 10.1002/Ana.410440722  0.397
1998 Djaldetti R, Melamed E. Management of response fluctuations: practical guidelines. Neurology. 51: S36-40. PMID 9711979 DOI: 10.1212/Wnl.51.2_Suppl_2.S36  0.394
1998 Hochman A, Sternin H, Gorodin S, Korsmeyer S, Ziv I, Melamed E, Offen D. Enhanced oxidative stress and altered antioxidants in brains of Bcl-2-deficient mice. Journal of Neurochemistry. 71: 741-8. PMID 9681465 DOI: 10.1046/J.1471-4159.1998.71020741.X  0.314
1998 Djaldetti R, Ziv I, Melamed E. Extreme anticipation in young-onset Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 13: 599-600. PMID 9613762 DOI: 10.1002/mds.870130339  0.339
1998 Offen D, Beart PM, Cheung NS, Pascoe CJ, Hochman A, Gorodin S, Melamed E, Bernard R, Bernard O. Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine neurotoxicity. Proceedings of the National Academy of Sciences of the United States of America. 95: 5789-94. PMID 9576963 DOI: 10.1073/Pnas.95.10.5789  0.369
1998 Shirvan A, Ziv I, Zilkha-Falb R, Machlyn T, Barzilai A, Melamed E. Expression of cell cycle-related genes during neuronal apoptosis: is there a distinct pattern? Neurochemical Research. 23: 767-77. PMID 9566617 DOI: 10.1023/A:1022415611545  0.322
1997 Ziv I, Offen D, Haviv R, Stein R, Panet H, Zilkha-Falb R, Shirvan A, Barzilai A, Melamed E. The proto-oncogene Bcl-2 inhibits cellular toxicity of dopamine: possible implications for Parkinson's disease. Apoptosis : An International Journal On Programmed Cell Death. 2: 149-55. PMID 14646549 DOI: 10.1023/A:1026408313758  0.424
1997 Ziv I, Offen D, Barzilai A, Haviv R, Stein R, Zilkha-Falb R, Shirvan A, Melamed E. Modulation of control mechanisms of dopamine-induced apoptosis--a future approach to the treatment of Parkinson's disease? Journal of Neural Transmission. Supplementum. 49: 195-202. PMID 9266428 DOI: 10.1007/978-3-7091-6844-8_20  0.43
1997 Ziv I, Barzilai A, Offen D, Nardi N, Melamed E. Nigrostriatal neuronal death in Parkinson's disease--a passive or an active genetically-controlled process? Journal of Neural Transmission. Supplementum. 49: 69-76. PMID 9266415 DOI: 10.1007/978-3-7091-6844-8_7  0.419
1997 Shirvan A, Ziv I, Machlin T, Zilkha-Falb R, Melamed E, Barzilai A. Two waves of cyclin B and proliferating cell nuclear antigen expression during dopamine-triggered neuronal apoptosis. Journal of Neurochemistry. 69: 539-49. PMID 9231711 DOI: 10.1046/J.1471-4159.1997.69020539.X  0.336
1997 Offen D, Ziv I, Barzilai A, Gorodin S, Glater E, Hochman A, Melamed E. Dopamine-melanin induces apoptosis in PC12 cells; possible implications for the etiology of Parkinson's disease. Neurochemistry International. 31: 207-16. PMID 9220453 DOI: 10.1016/S0197-0186(96)00150-7  0.393
1997 Offen D, Ziv I, Panet H, Wasserman L, Stein R, Melamed E, Barzilai A. Dopamine-induced apoptosis is inhibited in PC12 cells expressing Bcl-2. Cellular and Molecular Neurobiology. 17: 289-304. PMID 9187486 DOI: 10.1023/A:1026390201168  0.429
1997 Shirvan A, Ziv I, Barzilai A, Djaldeti R, Zilkh-Falb R, Michlin T, Melamed E. Induction of mitosis-related genes during dopamine-triggered apoptosis in sympathetic neurons. Journal of Neural Transmission. Supplementum. 50: 67-78. PMID 9120426 DOI: 10.1007/978-3-7091-6842-4_8  0.399
1997 Zilkha-Falb R, Ziv I, Nardi N, Offen D, Melamed E, Barzilai A. Monoamine-induced apoptotic neuronal cell death. Cellular and Molecular Neurobiology. 17: 101-18. PMID 9118202 DOI: 10.1023/A:1026333222008  0.394
1997 Ziv I, Zilkha-Falb R, Offen D, Shirvan A, Barzilai A, Melamed E. Levodopa induces apoptosis in cultured neuronal cells--a possible accelerator of nigrostriatal degeneration in Parkinson's disease? Movement Disorders : Official Journal of the Movement Disorder Society. 12: 17-23. PMID 8990049 DOI: 10.1002/mds.870120105  0.397
1997 Zilkha-Falb R, Shirvan A, Djaldeti R, Ziv I, Machlin T, Melamed E, Barzilai A. Induction of T-complex protein-1 (TCP-1) expression during dopamine-triggered neuronal apoptosis in chick embryo sympathetic neurons Neuroscience Letters. 237. DOI: 10.1016/S0304-3940(97)90226-3  0.338
1997 Offen D, Beart P, Choung S, Pascoe C, Hochman A, Gorodin S, Melamed E, Bernard R, Bernard O. Transgenic mice expressing human BCL-2 in their neurons are resistant to neurotoxicity of 6-OH-dopamine and MPTP Neuroscience Letters. 237: S38. DOI: 10.1016/S0304-3940(97)90155-5  0.343
1996 Djaldetti R, Atlas D, Melamed E. Effect of subcutaneous administration of levodopa ethyl ester, a soluble prodrug of levodopa, on dopamine metabolism in rodent striatum: implication for treatment of Parkinson's disease. Clinical Neuropharmacology. 19: 65-71. PMID 8867519 DOI: 10.1097/00002826-199619010-00005  0.435
1996 Offen D, Ziv I, Sternin H, Melamed E, Hochman A. Prevention of dopamine-induced cell death by thiol antioxidants: possible implications for treatment of Parkinson's disease. Experimental Neurology. 141: 32-9. PMID 8797665 DOI: 10.1006/Exnr.1996.0136  0.405
1996 Djaldetti R, Baron J, Ziv I, Melamed E. Gastric emptying in Parkinson's disease: patients with and without response fluctuations. Neurology. 46: 1051-4. PMID 8780089 DOI: 10.1212/WNL.46.4.1051  0.304
1996 Ziv I, Barzilai A, Offen D, Stein R, Achiron A, Melamed E. Dopamine-induced, genotoxic activation of programmed cell death. A role in nigrostriatal neuronal degeneration in Parkinson's disease? Advances in Neurology. 69: 229-33. PMID 8615132  0.306
1996 Djaldetti R, Melamed E. Levodopa ethylester: a novel rescue therapy for response fluctuations in Parkinson's disease. Annals of Neurology. 39: 400-4. PMID 8602763 DOI: 10.1002/ana.410390321  0.36
1995 Djaldetti R, Koren M, Ziv I, Achiron A, Melamed E. Effect of cisapride on response fluctuations in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 10: 81-4. PMID 7885359 DOI: 10.1002/mds.870100113  0.338
1995 Offen D, Ziv I, Gorodin S, Barzilai A, Malik Z, Melamed E. Dopamine-induced programmed cell death in mouse thymocytes. Biochimica Et Biophysica Acta. 1268: 171-7. PMID 7662705 DOI: 10.1016/0167-4889(95)00075-4  0.363
1995 Zoldan J, Friedberg G, Livneh M, Melamed E. Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3 receptor antagonist. Neurology. 45: 1305-8. PMID 7617188 DOI: 10.1212/WNL.45.7.1305  0.311
1994 Ziv I, Achiron A, Djaldetti R, Abraham M, Melamed E. Can nimodipine affect progression of motor neuron disease? A double-blind pilot study. Clinical Neuropharmacology. 17: 423-8. PMID 9316691 DOI: 10.1097/00002826-199410000-00004  0.335
1994 Achiron A, Margalit R, Hershkoviz R, Markovits D, Reshef T, Melamed E, Cohen IR, Lider O. Intravenous immunoglobulin treatment of experimental T cell-mediated autoimmune disease. Upregulation of T cell proliferation and downregulation of tumor necrosis factor alpha secretion. The Journal of Clinical Investigation. 93: 600-5. PMID 8113397 DOI: 10.1172/Jci117012  0.303
1994 Ziv I, Melamed E, Nardi N, Luria D, Achiron A, Offen D, Barzilai A. Dopamine induces apoptosis-like cell death in cultured chick sympathetic neurons--a possible novel pathogenetic mechanism in Parkinson's disease. Neuroscience Letters. 170: 136-40. PMID 8041491 DOI: 10.1016/0304-3940(94)90258-5  0.419
1994 Djaldetti R, Achiron A, Ziv I, Melamed E. First emergence of "delayed-on" and "dose failure" phenomena in a patient with Parkinson's disease following vagotomy. Movement Disorders : Official Journal of the Movement Disorder Society. 9: 582-3. PMID 7990855 DOI: 10.1002/mds.870090513  0.32
1994 Achiron A, Gilad R, Margalit R, Gabbay U, Sarova-Pinhas I, Cohen IR, Melamed E, Lider O, Noy S, Ziv I. Intravenous gammaglobulin treatment in multiple sclerosis and experimental autoimmune encephalomyelitis: delineation of usage and mode of action. Journal of Neurology, Neurosurgery, and Psychiatry. 57: 57-61. PMID 7964856 DOI: 10.1136/jnnp.57.Suppl.57  0.304
1993 Ziv I, Achiron A, Djaldetti R, Dressler R, Melamed E. Short-term beneficial effect of deprenyl monotherapy in early Parkinson's disease: a quantitative assessment. Clinical Neuropharmacology. 16: 54-60. PMID 8422657 DOI: 10.1097/00002826-199302000-00006  0.337
1993 Achiron A, Ziv I, Goren M, Goldberg H, Zoldan Y, Sroka H, Melamed E. Primary progressive freezing gait. Movement Disorders : Official Journal of the Movement Disorder Society. 8: 293-7. PMID 8341293 DOI: 10.1002/mds.870080307  0.33
1993 Zoldan J, Friedberg G, Goldberg-Stern H, Melamed E. Ondansetron for hallucinosis in advanced Parkinson's disease. Lancet. 341: 562-3. PMID 8094803 DOI: 10.1016/0140-6736(93)90327-D  0.337
1992 Melamed E. Biochemical and functional differences between dopamine formed from endogenous tyrosine and exogenous L-dopa in nigrostriatal dopaminergic neurons. Neurochemistry International. 20: 115S-117S. PMID 1365408 DOI: 10.1016/0197-0186(92)90222-D  0.416
1991 Melamed E, Achiron A, Shapira A, Davidovicz S. Persistent and progressive parkinsonism after discontinuation of chronic neuroleptic therapy: An additional tardive syndrome? Clinical Neuropharmacology. 14: 273-278. PMID 1676933 DOI: 10.1097/00002826-199106000-00013  0.375
1990 Melamed E, Rosenthal J, Youdim MB. Immunity of fetal mice to prenatal administration of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Journal of Neurochemistry. 55: 1427-31. PMID 2398363 DOI: 10.1111/j.1471-4159.1990.tb03156.x  0.362
1988 Melamed E. Brain grafting may reverse loss of responsiveness to levodopa therapy in Parkinson's disease. Clinical Neuropharmacology. 11: 77-82. PMID 3280129 DOI: 10.1097/00002826-198802000-00008  0.433
1988 Siegal T, Melamed E, Sandbank U, Catane R. Early and delayed neurotoxicity of mitoxantrone and doxorubicin following subarachnoid injection. Journal of Neuro-Oncology. 6: 135-40. PMID 3225635 DOI: 10.1007/BF02327389  0.313
1988 Pikarsky E, Melamed E, Rosenthal J, Uzzan A, Michowiz SD. The neurotoxin MPTP does not affect striatal superoxide dismutase activity in mice. Neuroscience Letters. 82: 327-31. PMID 2827077 DOI: 10.1016/0304-3940(87)90277-1  0.383
1987 Kidron D, Melamed E. Forms of dystonia in patients with Parkinson's disease Neurology. 37: 1009-1009. PMID 3587617 DOI: 10.1212/Wnl.37.6.1009  0.357
1987 Melamed E, Soffer D, Rosenthal J, Pikarsky E, Reches A. Effect of intrastriatal and intranigral administration of synthetic neuromelanin on the dopaminergic neurotoxicity of MPTP in rodents. Neuroscience Letters. 83: 41-6. PMID 3502019 DOI: 10.1016/0304-3940(87)90213-8  0.38
1987 Melamed E, Pikarski E, Goldberg A, Rosenthal J, Uzzan A, Conforti N. Effect of serotonergic, corticostriatal and kainic acid lesions on the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) in mice. Brain Research. 399: 178-80. PMID 3492237 DOI: 10.1016/0006-8993(86)90615-3  0.376
1986 Melamed E, Youdim MB, Rosenthal J, Spanier I, Uzzan A, Globus M. In vivo effect of MPTP on monoamine oxidase activity in mouse striatum. Brain Research. 359: 360-3. PMID 3878183 DOI: 10.1016/0006-8993(85)91451-9  0.374
1986 Melamed E, Martinovits G, Pikarsky E, Rosenthal J, Uzzan A. Diphenylhydantoin and phenobarbital suppress the dopaminergic neurotoxicity of MPTP in mice. European Journal of Pharmacology. 128: 255-257. PMID 3491762 DOI: 10.1016/0014-2999(86)90773-9  0.371
1986 Martinovits G, Melamed E, Cohen O, Rosenthal J, Uzzan A. Systemic administration of antioxidants does not protect mice against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP). Neuroscience Letters. 69: 192-7. PMID 3489911 DOI: 10.1016/0304-3940(86)90602-6  0.328
1986 Melamed E, Bitton V, Zelig O. Delayed onset of responses to single doses of L-dopa in parkinsonian fluctuators on long-term L-dopa therapy. Clinical Neuropharmacology. 9: 182-188. PMID 3085928 DOI: 10.1097/00002826-198604000-00009  0.305
1986 Melamed E. Initiation of Levodopa Therapy in Parkinsonian Patients Should Be Delayed Until the Advanced Stages of the Disease Jama Neurology. 43: 402-405. PMID 3082315 DOI: 10.1001/Archneur.1986.00520040080025  0.316
1986 Melamed E, Globus M, Mildworf B. Regional cerebral blood flow in patients with Parkinson's disease under chronic levodopa therapy: measurements during "on" and "off" response fluctuations. Journal of Neurology, Neurosurgery, and Psychiatry. 49: 1301-1304. PMID 3025375 DOI: 10.1136/Jnnp.49.11.1301  0.345
1985 Globus M, Mildworf B, Melamed E. Cerebral blood flow and cognitive impairment in Parkinson's disease Neurology. 35: 1135-1135. PMID 4022347 DOI: 10.1212/Wnl.35.8.1135  0.317
1985 Melamed E, Hefti F. Altered pharmacokinetics of L-dopa metabolism. Neurology. 35: 939-41. PMID 4000502 DOI: 10.1212/Wnl.35.6.939-A  0.484
1985 Melamed E, Rosenthal J, Cohen O, Uzzan A, Globus M. Amphetamine, but not reserpine, protects mice against dopaminergic neurotoxicity of MPTP. Neuropharmacology. 24: 923-5. PMID 3877249 DOI: 10.1016/0028-3908(85)90047-4  0.363
1985 Melamed E, Rosenthal J, Cohen O, Mordechai G, Uzzan A. Dopamine but not norepinephrine or serotonin uptake inhibitors protect mice against neurotoxicity of MPTP. European Journal of Pharmacology. 116: 179-181. PMID 3876943 DOI: 10.1016/0014-2999(85)90201-8  0.376
1985 Melamed E, Rosenthal J, Globus M, Cohen O, Frucht Y, Uzzan A. Mesolimbic dopaminergic neurons are not spared by MPTP neurotoxicity in mice. European Journal of Pharmacology. 114: 97-100. PMID 3876229 DOI: 10.1016/0014-2999(85)90528-X  0.38
1985 Melamed E, Rosenthal J, Globus M, Cohen O, Uzzan A. Suppression of MPTP-induced dopaminergic neurotoxicity in mice by nomifensine and L-DOPA. Brain Research. 342: 401-4. PMID 3876139 DOI: 10.1016/0006-8993(85)91146-1  0.413
1985 Hefti F, Enz A, Melamed E. Partial lesions of the nigrostriatal pathway in the rat. Acceleration of transmitter synthesis and release of surviving dopaminergic neurones by drugs. Neuropharmacology. 24: 19-23. PMID 2858830 DOI: 10.1016/0028-3908(85)90090-5  0.535
1984 Melamed E, Frucht Y, Lemor M, Uzzan A, Rosenthal Y. Dopamine turnover in rat retina: A 24-hour light-dependent rhythm Brain Research. 305: 148-151. PMID 6744054 DOI: 10.1016/0006-8993(84)91130-2  0.308
1984 Melamed E, Hefti F, Bitton V, Globus M. Suppression of L-dopa-induced circling in rats with nigral lesions by blockade of central dopa-decarboxylase: implications for mechanism of action of L-dopa in parkinsonism. Neurology. 34: 1566-70. PMID 6504328 DOI: 10.1212/WNL.34.12.1566  0.579
1983 Melamed E, Durst R, Frucht Y, Globus M. Differential effect of acute and chronic haloperidol administration on dopamine turnover in rat nigrostriatal and retinal dopaminergic neurons. European Journal of Pharmacology. 89: 279-282. PMID 6873163 DOI: 10.1016/0014-2999(83)90506-X  0.376
1983 Melamed E, Globus M, Friedlender E, Rosenthal J. Chronic L‐dopa administration decreases striatal accumulation of dopamine from exogenous L‐dopa in rats with intact nigrostriatal projections Neurology. 33: 950-950. PMID 6683384 DOI: 10.1212/Wnl.33.7.950  0.381
1983 Globus M, Melamed E, Conforti N. Effect of decortication on striatal dopamine turnover. Clinical Neuropharmacology. 6: 247-252. PMID 6627233 DOI: 10.1097/00002826-198309000-00007  0.416
1983 Globus M, Melamed E. Combined administration of direct dopamine receptor agonists and L-dopa does not interfere with utilization of exogenous L-dopa in rat corpus striatum. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 7: 211-5. PMID 6310691 DOI: 10.1016/0278-5846(83)90109-4  0.402
1982 Lichtensteiger W, Hefti F, Felix D, Huwyler T, Melamed E, Schlumpf M. Stimulation of nigrostriatal dopamine neurones by nicotine. Neuropharmacology. 21: 963-8. PMID 7145035 DOI: 10.1016/0028-3908(82)90107-1  0.551
1982 Melamed E, Hefti F, Bird ED. Huntington chorea is not associated with hyperactivity of nigrostriatal dopaminergic neurons: studies in postmortem tissues and in rats with kainic acid lesions. Neurology. 32: 640-4. PMID 6211637 DOI: 10.1212/WNL.32.6.640  0.597
1982 Growdon JH, Melamed E, Logue M, Hefti F, Wurtman RJ. Effects of oral L-tyrosine administration on CSF tyrosine and homovanillic acid levels in patients with Parkinson's disease. Life Sciences. 30: 827-32. PMID 6175872 DOI: 10.1016/0024-3205(82)90596-3  0.714
1982 Melamed E, Hefti F, Wurtman RJ. Compensatory mechanisms in the nigrostriatal dopaminergic system in Parkinson's disease: studies in an animal model. Israel Journal of Medical Sciences. 18: 159-63. PMID 6121770  0.567
1982 Hefti F, Melamed E. Chronic dopa feeding of mice Neurology. 32: 685-685. DOI: 10.1212/WNL.32.6.685  0.465
1981 Hefti F, Melamed E. Dopamine release in rat striatum after administration of L-dope as studied with in vivo electrochemistry. Brain Research. 225: 333-46. PMID 7306794 DOI: 10.1016/0006-8993(81)90840-4  0.579
1981 Hefti F, Melamed E, Wurtman RJ. The site of dopamine formation in rat striatum after L-dopa administration. The Journal of Pharmacology and Experimental Therapeutics. 217: 189-97. PMID 7205652  0.553
1981 Melamed E, Hefti F, Pettibone DJ, Liebman J, Wurtman RJ. Aromatic L-amino acid decarboxylase in rat corpus striatum: implications for action of L-dopa in parkinsonism. Neurology. 31: 651-5. PMID 7195482 DOI: 10.1212/WNL.31.6.651  0.747
1981 Hefti F, Melamed E, Bhawan J, Wurtman RJ. Long-term administration of L-DOPA does not damage dopaminergic neurons in the mouse Neurology. 31: 1194-1194. DOI: 10.1212/WNL.31.9.1194  0.653
1981 Hefti F, Melamed E. Reply from Hefti and Melamed Trends in Neurosciences. 4: 150. DOI: 10.1016/0166-2236(81)90050-3  0.423
1980 Melamed E, Hefti F, Wurtman RJ. Decarboxylation of exogenous L-DOPA in rat striatum after lesions of the dopaminergic nigrostriatal neurons: the role of striatal capillaries. Brain Research. 198: 244-8. PMID 7407592 DOI: 10.1016/0006-8993(80)90363-7  0.668
1980 Melamed E, Hefti F, Wurtman RJ. Diminished decarboxylation of L-DOPA in rat striatum after intrastriatal injections of kainic acid. Neuropharmacology. 19: 409-11. PMID 7383284 DOI: 10.1016/0028-3908(80)90194-X  0.662
1980 Melamed E, Hefti F, Wurtman RJ. L-3,4-Dihydroxyphenylalanine and L-5-hydroxytryptophan decarboxylase activities in rat striatum: effect of selective destruction of dopaminergic or serotoninergic input. Journal of Neurochemistry. 34: 1753-6. PMID 7381499 DOI: 10.1111/j.1471-4159.1980.tb11270.x  0.608
1980 Melamed E, Glaeser B, Growdon JH, Wurtman RJ. Plasma tyrosine in normal humans: effects of oral tyrosine and protein-containing meals. Journal of Neural Transmission. 47: 299-306. PMID 7190187 DOI: 10.1007/BF01247323  0.579
1980 Hefti F, Melamed E, Sahakian BJ, Wurtman RJ. Circling behavior in rats with partial, unilateral nigro-striatal lesions: effect of amphetamine, apomorphine, and DOPA. Pharmacology, Biochemistry, and Behavior. 12: 185-8. PMID 7189592 DOI: 10.1016/0091-3057(80)90353-6  0.684
1980 Hefti F, Melamed E, Wurtman RJ. The decarboxylation of DOPA in the parkinsonian brain: in vivo studies on an animal model. Journal of Neural Transmission. Supplementum. 95-101. PMID 6776238 DOI: 10.1007/978-3-7091-8582-7_10  0.667
1980 Melamed E, Hefti F, Wurtman RJ. Nonaminergic striatal neurons convert exogenous L-dopa to dopamine in parkinsonism. Annals of Neurology. 8: 558-63. PMID 6260009 DOI: 10.1002/ana.410080603  0.68
1980 Melamed E, Hefti F, Wurtman RJ. Tyrosine administration increases striatal dopamine release in rats with partial nigrostriatal lesions. Proceedings of the National Academy of Sciences of the United States of America. 77: 4305-9. PMID 6254020 DOI: 10.1073/PNAS.77.7.4305  0.662
1980 Wurtman RJ, Hefti F, Melamed E. Precursor control of neurotransmitter synthesis. Pharmacological Reviews. 32: 315-35. PMID 6115400  0.49
1980 Hefti F, Melamed E, Wurtman RJ. Partial lesions of the dopaminergic nigrostriatal system in rat brain: biochemical characterization. Brain Research. 195: 123-37. PMID 6105003 DOI: 10.1016/0006-8993(80)90871-9  0.676
1980 Melamed E, Hefti F, Liebman J, Schlosberg AJ, Wurtman RJ. Serotonergic neurones are not involved in action of L-dopa in Parkinson's disease. Nature. 283: 772-4. PMID 6101905 DOI: 10.1038/283772A0  0.687
1980 Hefti F, Melamed E. l-DOPA's mechanism of action in Parkinson's disease Trends in Neurosciences. 3: 229-231. DOI: 10.1016/S0166-2236(80)80070-1  0.549
1979 Glaeser BS, Melamed E, Growdon JH, Wurtman RJ. Elevation of plasma tyrosine after a single oral dose of L-tyrosine. Life Sciences. 25: 265-71. PMID 481129 DOI: 10.1016/0024-3205(79)90294-7  0.559
1979 Lavy S, Melamed E, Cooper G, Bentin S, Rinot Y. Regional cerebral blood flow in patients with Parkinson's disease. Archives of Neurology. 36: 344-8. PMID 454231 DOI: 10.1001/archneur.1979.00500420054005  0.361
1979 Melamed E. Early-morning dystonia. A late side effect of long-term levodopa therapy in Parkinson's disease. Jama Neurology. 36: 308-310. PMID 444100 DOI: 10.1001/Archneur.1979.00500410086014  0.351
1979 Moskowitz MA, Reinhard JF, Romero J, Melamed E, Pettibone DJ. Neurotransmitters and the fifth cranial nerve: is there a relation to the headache phase of migraine? Lancet. 2: 883-5. PMID 90971 DOI: 10.1016/S0140-6736(79)92692-8  0.615
Show low-probability matches.